Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia

被引:37
作者
Suzuki, T [1 ]
Uchida, H [1 ]
Tanaka, KF [1 ]
Tomita, M [1 ]
Tsunoda, K [1 ]
Nomura, K [1 ]
Takano, H [1 ]
Tanabe, A [1 ]
Watanabe, K [1 ]
Yagi, G [1 ]
Kashima, H [1 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Shinjuku Ku, Tokyo 1608582, Japan
关键词
antipsychotics; dose reduction; high-dose therapy; polypharmacy; schizophrenia; FLUPHENAZINE DECANOATE; COMBINATION THERAPY; MENTAL-HEALTH; HALOPERIDOL; DOSAGE; TRIAL;
D O I
10.1097/00004850-200311000-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antipsychotic medications are often used at higher than the recommended dose and sometimes in a combination regimen to treat schizophrenia. However, in general, highdose therapies have been abandoned in recent clinical studies. In this study, dose reduction of antipsychotic medication was implemented for patients with chronic schizophrenia, most of whom (81%) had been treated with an antipsychotic high-dose polypharmacy regimen consisting of more than 1000 mg/day in total amount. The results show that merely reducing the amount of antipsychotic led to favourable outcome in 23 out of 41 cases (56%), with another 13 cases (32%) showing no change. Dose reduction ended in failure in only five subjects (112%). Overall, the amount as well as the number of antipsychotic medications was significantly reduced from 1984 mg to 812 mg per day (reductions of 59% and from 3.6 to 2.2, respectively; both P<0.0001). The Global Assessment of Functioning scale improved from 30.6 to 372, which reached significance (P<0.001). Accordingly, the Severity of Illness improved from 4.7 to 4.2, and was also significant (P<0.01). Dose reduction is an encouraging strategy to consider for those patients with schizophrenia who have chronically been treated with high-dose antipsychotic polypharmacy, even if judged unavoidable in the past. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:323 / 329
页数:7
相关论文
共 36 条
[1]  
AYRD FJ, 1958, DIS NERV SYST, V16, P146
[2]  
BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79
[3]  
Carpenter WT, 1999, AM J PSYCHIAT, V156, P412
[4]   Recent trends in antipsychotlic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy [J].
Clark, RE ;
Bartels, SJ ;
Mellman, TA ;
Peacock, WJ .
SCHIZOPHRENIA BULLETIN, 2002, 28 (01) :75-84
[5]   Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations [J].
Freudenreich, O ;
Goff, DC .
ACTA PSYCHIATRICA SCANDINAVICA, 2002, 106 (05) :323-330
[6]  
Guy W., 1976, CGI CLIN GLOBAL IMPR, P217
[7]  
Herz MI, 1997, AM J PSYCHIAT, V154, P1
[8]   The Dose Reduction in Schizophrenia (DORIS) study: A final report [J].
Hirschowitz, J ;
Hitzemann, R ;
Piscani, K ;
Burr, G ;
Frecska, E ;
Culliton, D ;
Mann, M ;
Curtis, C .
SCHIZOPHRENIA RESEARCH, 1997, 23 (01) :31-43
[9]  
HOGARTY GE, 1988, ARCH GEN PSYCHIAT, V45, P797
[10]  
INAGAKI A, 2001, 2001 C INT NEUR CINP, P21